drugset / Trial / NCT01815359
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Phase 2
Active not recruiting
292 enrolled
Memorial Sloan Kettering Cancer Center
Brigham and Women's Hospital · collabThe Cleveland Clinic · collabUniversity of Miami · collabUniversity of Pittsburgh Medical Center · collabWashington University School of Medicine · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.
Timeline
- Start
- 2013-03
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Mitomycin C | Other / unclassified | — | — |